ALVR News and Press, AlloVir Inc. From 08/21/23

AlloVir, Inc. (NASDAQ: ALVR) is one of today's top gainers. The company's shares are currently up 22.54% on the day to $3.48. Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies t...

2023-08-21 11:52:45 ET More on Health Care Select Sector SPDR XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air Goldman add...

2023-08-18 10:19:27 ET Gainers: Aditxt ( ADTX ) +50% . AlloVir ( ALVR ) +18% . Agenus ( AGEN ) +7% . Veru ( VERU ) +7% . Akari Therapeutics ( AKTX ) +6% . Losers: Evelo Biosciences ( EVLO ) -37% . Diffusi...

2023-08-18 10:05:13 ET More on AlloVir AlloVir: 'Takes One To Know One' AlloVir: Several Late-Stage Programs Make This Worth A Look AlloVir spikes as Gilead buys over $10M stock AlloVir gains after long-term mortality data for lead asset AlloVir falls...

2023-08-03 10:17:06 ET AlloVir press release ( NASDAQ: ALVR ): Q2 GAAP EPS of -$0.48. As of June 30, 2023, AlloVir had cash, cash equivalents, and short-term investments of $246.5 million, compared with  $233.8 million as of December 31, 2022. For fiscal year 2023...

Company's three Phase 3 global registrational trials for its allogeneic, off-the-shelf, virus-specific T cell therapy, posoleucel, in three distinct, first-to-market indications in allo-HCT patients continue to enroll, with data anticipated in second half of 2024 Positive data from the Ph...

2023-07-19 17:30:09 ET Gainers: Zions Bancorporation ( ZION ) +8% . Heritage-Crystal Clean ( HCCI ) +7% . CareMax ( CMAX ) +5% . Cabaletta  ( CABA ) +5% . AlloVir ( ALVR ) +4% . Losers: Richardson Electronics ( REL...

2023-07-10 19:13:34 ET Summary Gilead has purchased $10.9 million in shares of Allovir, a biotech company specializing in cell therapy and organ transplant, giving it a 15% ownership of the company. Allovir's lead product, posoleucel, is in Phase III clinical trials and targets si...

2023-07-01 03:48:14 ET Summary Positive final results from the phase 2 study, using posoleucel for BK Virus, were presented at the American Transplant Congress 2023. Discussions with FDA and key opinion leaders to align on phase 3 study design of posoleucel for BK Virus are ongoin...

2023-06-29 09:29:22 ET Cell therapy developer Allovir, Inc. ( NASDAQ: ALVR ) added ~11% pre-market Thursday after Gilead ( NASDAQ: GILD ) disclosed the purchase of ~$11M worth of company stock. According to an SEC filing on Wednesday, the drugmaker has bought ~2.9M All...